Payers' Guide

FDA Approvals, Drug Updates, Payers' Guide

Trends in the 2013 Pharmaceutical Pipeline

Dalia Buffery, MA, ABD, Atheer A. Kaddis, PharmD

Select Drug Profiles, Payers' Guide

Iclusig: A New Treatment Option for Adults with CML or Ph+ ALL that Is Resistant/ Intolerant to Previous Therapy with TKIs

Lynne Lederman, PhD, Medical Writer

Select Drug Profiles, Payers' Guide

Qsymia: Combination Oral Therapy a New Weight-Loss Option for Obese or Overweight Patients

Select Drug Profiles, Payers' Guide

Rayos: A Novel Oral Delayed-Release Prednisone for the Treatment of Rheumatoid Arthritis and Other Inflammatory Diseases

Alice Goodman, Medical Writer

Select Drug Profiles, Payers' Guide

Xeljanz: A New Treatment Option for Patients with Rheumatoid Arthritis

Alice Goodman, Medical Writer

Select Drug Profiles, Payers' Guide

Tudorza Pressair: A Novel Oral Inhalation Therapy for the Maintenance Treatment of Chronic Obstructive Pulmonary Disease–Associated Bronchospasm

Select Drug Profiles, Payers' Guide

Vascepa: First EPA-Only Omega-3 Therapy Approved by the FDA for Severe Hypertriglyceridemia

Select Drug Profiles, Payers' Guide

Zaltrap: A New Option for the Treatment of Patients with Metastatic Colorectal Cancer Resistant to or Progressing After an Oxaliplatin-Containing Regimen

Lynne Lederman, PhD, Medical Writer

Select Drug Profiles, Payers' Guide

Zytiga Receives an Expanded Indication for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy

Select Drug Profiles, Payers' Guide

Zioptan Receives FDA Approval for Patients with Open-Angle Glaucoma and/or Ocular Hypertension

1
2
3
4
5

Page 2 of 19
Results 11 - 20 of 185

SUBSCRIBE

© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

AHDB Print Edition

AHDB Weekly e‑Newsletter

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.